Your session is about to expire
← Back to Search
LYL797 for Breast and Lung Cancer
Study Summary
This trial will study a new cancer treatment, called LYL797, in patients who have triple negative breast cancer or non-small cell lung cancer that has come back or does not respond to other treatments. The first part of the trial will test different doses of LYL797 to find a safe dose. The second part of the trial will give that dose to additional patients to see if it is effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am on long-term blood thinners like warfarin.I am fully active or can carry out light work.I do not have active, untreated brain cancer spread but stable, treated brain involvement is okay.I have not had T-cell or anti-ROR1 therapy before.I am 18 years old or older.I have had a solid organ transplant.I am of childbearing age and my pregnancy test was negative.I do not have an active infection.You have HIV, HTLV-1, active hepatitis B or C, or active tuberculosis.I have heart problems that affect my daily activities.My cancer is triple-negative breast cancer or non-small cell lung cancer, cannot be surgically removed, and tests positive for ROR1.I have fluid buildup around my lungs or heart that isn't managed.I have at least two detectable cancer lesions.I haven't taken steroids or immunosuppressants in the last 14 days.My organs and bone marrow are working well.
- Group 1: Experimental LYL797
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any available openings for prospective patients in this trial?
"Confirmed, as per clinicaltrials.gov this experiment is actively recruiting participants. It was initially published on March 29th 2022 and the last update to its information came on November 11th of the same year."
How many participants have signed up for this trial?
"The sponsor of this medical study, Lyell Immunopharma Inc., is aiming to recruit 54 participants across two sites: the Karmanos Cancer Institute in Detroit and MD Anderson Cancer Center in Arizona. In order for these individuals to be eligible, they must meet all specified criteria."
Has the Food and Drug Administration issued a green light for LYL797?
"The safety of LYL797 was given a rating of 1, as it is currently in Phase 1 trials with limited evidence for its efficacy and security."
To what extent have hospitals implemented this trial?
"This clinical trial is presently recruiting participants from 12 different medical centres, 3 of which are in Detroit, Scottsdale and Houston. It might be prudent to select the closest clinic so that you can minimize travel requirements if accepted as a participant."
What is the projected outcome of this clinical experiment?
"This two-year assessment will evaluate the emergence of adverse effects (TEAEs) associated with treatment. The secondary objectives are to measure progression-free survival, concentration time curves in peripheral blood samples, and persistence of LYL797 CAR T cells within those same specimens."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Sidney Kimmel Cancer Center, Jefferson University Hospital: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger